Phylinda L. Chan
Pfizer (United Kingdom)(GB)
Research Areas
SARS-CoV-2 and COVID-19 Research, Computational Drug Discovery Methods, COVID-19 Clinical Research Studies, SARS-CoV-2 detection and testing, Cancer therapeutics and mechanisms
Most-Cited Works
- → Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir(2022)153 cited
- → Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment(2022)65 cited
- → Innovative Randomized Phase 1 Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir(2022)6 cited